Stifel Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

June 15, 2026 9:32 AM

Stifel analyst Stephen Willey reiterated a Buy rating and $46.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).The analyst commented, "The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found